AXNX - Axonics Modulation Technologies, Inc.
| Previous Close | 30.27 |
| Open | 30.45 |
| Bid | 20.29 x 800 |
| Ask | 35.13 x 900 |
| Day's Range | 30.45 - 32.34 |
| 52 Week Range | 11.95 - 32.90 |
| Volume | 186,186 |
| Avg. Volume | 129,170 |
| Market Cap | 893.199M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.94 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.25 |
- Associated Press•17 days ago
Axonics: 1Q Earnings Snapshot
The Irvine, California-based company said it had a loss of 47 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- Business Wire•17 days ago
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. , a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation device for the treatment of urinary and bowel dysfunction, reported today financial results for the first quarter ended March 31, 2019, and provided an update on operational initiatives.
- Business Wire•20 days ago
Axonics® Announces ARTISAN-SNM Pivotal Study Results Presented at the American Urological Association Annual Meeting
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced the presentation of positive results from the ARTISAN-SNM pivotal study, designed to gain market approval from the U.S. Food & Drug Administration (FDA) for the Axonics r-SNM® System1. ARTISAN-SNM study results were presented on May 5 at the 2019 American Urological Association (AUA) Annual Meeting in Chicago by Professor Howard Goldman, M.D., of the Cleveland Clinic.
- Business Wire•25 days ago
Axonics® to Present at Upcoming Investor Conferences
Raymond W. Cohen, Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 10:15 am PDT at the Encore in Las Vegas. Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction.
- Business Wire•last month
Axonics® to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the first quarter of 2019 and provide an update on operations and FDA regulatory status after the market closes on Wednesday, May 8, 2019. In conjunction with the release, the Company will host a conference call with the investment community that same day at 4:30 p.m. Eastern Time to discuss the financial results and current business developments. A live webcast of the call may be accessed by visiting the Events & Presentations page of the investors section of the Company's website at ir.axonicsmodulation.com.
- Business Wire•2 months ago
Welkin Health Announces Partnership to Implement an Innovative Program to Support Commercialization of the Axonics® Cutting-Edge Sacral Neuromodulation Therapy
Welkin’s software will streamline workflows for care teams and enable personalized, ongoing support for patients receiving therapy for urinary and fecal dysfunction
- Business Wire•2 months ago
Axonics® Appoints Nancy L. Snyderman, M.D. and Jane E. Kiernan to its Board of Directors
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Nancy L. Snyderman, M.D. and Jane E. Kiernan have been appointed to the Axonics board of directors, effective immediately. Concurrent with this appointment, Shahzad Malik, M.D., general partner with Advent Life Sciences (London), and Geoff Pardo, partner with Gilde Healthcare (Boston), members of the board of directors since 2015 and 2017, respectively, have retired from the Axonics board and will not stand for re-election at the Axonics annual shareholder meeting planned for August 19, 2019.
- Business Wire•2 months ago
Axonics® to Present at the Needham Healthcare Conference
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that members of the management team will present at the 18th Annual Needham Healthcare Conference, Wednesday, April 10, at 10:40 a.m. ET in New York City, and will be available for one-on-one meetings. Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction.
- Business Wire•3 months ago
Axonics® to Participate in Upcoming Investor Events
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM® System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling.
- Business Wire•3 months ago
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. , a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, reported today financial results for the fourth quarter and year ended December 31, 2018, and provided an update on operational initiatives.
- Business Wire•3 months ago
Axonics® Appoints Michael H. Carrel to its Board of Directors
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Michael H. Carrel has been appointed to the Axonics board of directors, effective immediately. Mr. Carrel has served as the president and CEO and member of the board of AtriCure, Inc. (ATRC) since late 2012.
- Zacks•3 months ago
Ciena (CIEN) to Report Q1 Earnings: A Beat in the Offing?
Ciena's (CIEN) fiscal first-quarter earnings are likely to gain from year-over-year higher revenues resulting from its long-term investments to meet customer needs.
- Business Wire•3 months ago
Axonics® Submits Pivotal Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of pivotal clinical data from the ARTISAN-SNM pivotal clinical study designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1. The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal clinical study approved under an FDA Investigational Device Exemption (“IDE”) to evaluate the safety and efficacy of the Axonics r-SNM System for urinary dysfunction.
- Business Wire•3 months ago
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system.
- Business Wire•3 months ago
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, disclosed today positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System1. The clinical study demonstrated that patients implanted with the Axonics r-SNM System received clinically meaningful and statistically significant improvements in Urinary Urgency Incontinence (“UUI”) symptoms and quality of life. The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal clinical study approved under an FDA Investigational Device Exemption (“IDE”) to evaluate the safety and efficacy of the Axonics r-SNM System for urinary dysfunction.
- Business Wire•3 months ago
Axonics® to Report 2018 Fourth Quarter and Full-Year Financial Results and Host a Conference Call on March 5
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the 2018 fourth quarter and full year after the market closes on Tuesday, March 5, 2019. In conjunction with the release, the Company will host a conference call with the investment community that same day at 4:30 p.m. Eastern Time to discuss the financial results and recent business developments.
- Business Wire•3 months ago
Axonics® Submits Full Body MRI Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of complete test data to the U.S. Food & Drug Administration (“FDA”) for the purpose of gaining Conditional Full Body Magnetic Resonance Imaging (“MRI”) labeling approval for the Axonics r-SNM® System1 for urinary and bowel dysfunction. This data was submitted as an amendment to the Company’s previously filed premarket approval application (“PMA”).
- Simply Wall St.•4 months ago
What Kind Of Shareholders Own Axonics Modulation Technologies, Inc. (NASDAQ:AXNX)?
If you want to know who really controls Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), then you'll have to look at the makeup of its share registry. Institutions will often hold stock Read More...
- Business Wire•5 months ago
Axonics® Submits Interim Clinical Data to U.S. Food & Drug Administration for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the submission of interim clinical data from the ARTISAN-SNM pivotal clinical study to the U.S. Food & Drug Administration (“FDA”). The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal clinical study, approved under an FDA Investigational Device Exemption (“IDE”) to evaluate the safety and efficacy of the Axonics r-SNM® System1 for urinary dysfunction.
- Business Wire•5 months ago
Axonics® Announces Third Quarter 2018 Financial Results and Operational Update
Axonics Modulation Technologies, Inc. a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation devices for the treatment of urinary and bowel dysfunction, reported today financial results for the quarter ended September 30, 2018 and provided an update on operational initiatives.
- Business Wire•5 months ago
Axonics® Announces Publication of NICE Briefing
The U.K.’s National Institute for Health and Care Excellence Published a Medtech Innovation Briefing on the Axonics r-SNM® System
- Business Wire•6 months ago
Axonics® to Report Third Quarter 2018 Results and Provide Business Update on December 11
Axonics Modulation Technologies, Inc., (AXNX) developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the third quarter 2018 after the market closes on Tuesday, December 11, 2018. For more information, visit the Company’s website at www.axonicsmodulation.com.
- Business Wire•6 months ago
Axonics® Files for Premarket Approval with U.S. Food & Drug Administration for its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the design, development and commercialization of rechargeable implantable Sacral Neuromodulation (“SNM”) solutions for the treatment of urinary and bowel dysfunction, today announced that on December 3, 2018, the Company submitted a premarket approval application (“PMA”) to the U.S. Food & Drug Administration (“FDA”) for the Axonics r-SNM® System, an investigational medical device. This PMA filing submitted by Axonics is referred to as a “literature-based PMA”. While most PMAs are supported by original clinical investigations, in rare cases, literature-based evidence may be accepted as the sole basis for approval of a PMA to establish reasonable assurance of safety and effectiveness when the literature is sufficient, detailed, objective, and directly applicable to the subject device.
- Business Wire•6 months ago
Axonics® Announces Listing on the U.K.’s National Health Service Supply Chain for Its Sacral Neuromodulation System
Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions for the treatment of urinary and bowel dysfunction, announced today that the Axonics r-SNM™ System has been listed on the U.K.’s National Health Service Supply Chain (“NHS SC”) online catalogue, thereby allowing wide commercial distribution to NHS hospitals in England. Listing on the NHS SC online catalogue is a key step toward broader availability of new medical technologies and orders for the Company’s product are already being received and shipped. The Axonics r-SNM System is the first rechargeable SNM system approved for sale in the U.K. for patients suffering from overactive bladder, fecal incontinence and urinary retention.
- Business Wire•6 months ago
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics Modulation Technologies, Inc. , a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation solutions for the treatment of overactive bladder , fecal incontinence , and urinary retention , today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional ...
